Lophius Biosciences Appoints Robert J. Silverman as Supervisory Board Member


Lophius Biosciences GmbH, a privately held biotech company focusing on the development and marketing of innovative T cell-based diagnostic systems, today announced that Robert J. Silverman, former CEO of mtm Laboratories AG, was appointed to the Company’s Supervisory Board.

Mr. Silverman has over 30 years of leadership experience in private and public companies across multiple segments of the healthcare industry. Currently he serves on the board of several early stage companies, including Chairman of Kiyatec, Inc., and as an Operational Partner with Gilde Healthcare, which recently closed a $285 Million fund. Mr. Silverman has considerable executive level experience in the diagnostic and pharmaceutical industry from his previous roles at Abbott Laboratories, Pasteur Merieux Connaught, Cytyc Corporation and mtm Laboratories. At mtm laboratories, an in vitro diagnostic company developing and commercializing tests for the detection and diagnosis of cervical cancer, he was instrumental as CEO in creating a successful business enterprise that resulted in the acquisition by Roche for $270 Million. He received his Bachelor of Science degree in Pharmacy from the University of Michigan, and a Master in Management from the JL Kellogg Graduate School of Management.

“On behalf of Lophius, I am pleased to welcome Bob on board. Bob has extraordinary business and operational expertise. Management and the board will greatly benefit from his broad experience as a value creating executive and as a strategic advisor in the diagnostic industry”, said Prof. Ralf Wagner, Chairman of the Lophius Biosciences Supervisory Board.

“The disruptive and proprietary technology platforms of Lophius enable the development of novel solutions in the emerging field of T cell based diagnostics. The potential exists to address significant unmet market needs, and this is greatly facilitated by the extended funding. I look forward to being a part of this exciting opportunity and to support this effort”, commented Bob Silverman, Member of the Lophius Biosciences Supervisory Board.



March 29, 2017


Topic Area: Press Release


Recent Posts

Healthcare and Resilience: A Pledge for Change

Climate resilience and reducing environmental impact drive voluntary program targeting hospitals.


Texas Health Resources Announces New Hospital for North McKinney

Expected to open in 2028, the hospital will feature 60 beds initially with plans to double in capacity to accommodate for future community growth.


Cedar Point Health Falls Victim to Data Breach

Cedar Point Health has no evidence directly linking this incident to specific incidents of financial fraud or identity theft.


Fire Protection in Healthcare: Why Active and Passive Systems Must Work as One

Sprinklers, smoke compartments and firestopping can form an interdependent safety strategy.


Cleveland Clinic Hits Key Milestones for Palm Beach County Expansion

These include plans to begin demolition of current structure and hospital site preparation in 2026 and open the outpatient center and ambulatory surgery center in 2027.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.